No photo of Jennifer Donglan Wu

View Scopus Profile

Jennifer Donglan Wu

  • 3498 Citations
1990 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

I joined Northwestern University in August 2017 as a tenured Professor in Urology. I previously served as a Professor of Microbiology and Immunology at the Medical University of South Carolina and the University of Washington. I obtained a PhD from the University of British Columbia in Canada followed by post-doctoral training in Fred Hutchinson Cancer Research Center (FHCRC) and a faculty position at the University of Washington. My research focuses on understanding how cancer cells edit the immune system with the ultimate goal to develop effective immune therapy to control cancers.

Research in my laboratory include these specific aspects: 1) mechanisms of cancer immune evasion; 2) development of novel cancer immunotherapy; 3) Immune therapy-related mucosal toxicity; 4) mechanisms of cancer therapeutic resistance; 4) cancer biomarker discovery. Prostate Cancer is one of my lab's main focus areas. I am also researching the NKG2D axis in tumors which can be applied to a broad spectrum of cancer types and autoimmunity.

Training Experience

2002Postdoctoral Fellowship, Fred Hutchinson Cancer Research Center

Education/Academic qualification

PhD, University of British Columbia

… → 2000

MSc, Peking University

… → 1991

Research interests

  • Cancer Biology
  • Immune Regulation
  • Inflammation
  • Inflammatory Bowel Disease
  • Interdisciplinary Research
  • Prostate Cancer

Fingerprint Dive into the research topics where Jennifer Donglan Wu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Pre-clinical development of a novel class of immunotherapeutic antibody for metastatic prostate cancer

Wu, J. D.

CanCure LLC, National Cancer Institute

11/8/19 → 8/31/21

Project: Research project

    • Prostate Cancer Research Program: Idea Development Award

    Wu, J. D.

    Washington University St. Louis, U.S. Army Medical Research and Materiel Command

    9/30/19 → 9/29/22

    Project: Research project

    • Enhancing Anti-CTLA4 Immunology Therapy for Prostate Cancer with Cotargeting Soluble NKG2D Ligand

    Wu, J. D.

    U.S. Army Medical Research and Materiel Command

    10/1/18 → 10/31/20

    Project: Research project

    • Faculty Developmental Fund Recipient Y24 C

    Wu, J. D.

    National Cancer Institute

    8/10/18 → 7/31/23

    Project: Research project

    • Target MIC shedding to revive anti-tumor immunity

    Wu, J. D.

    National Cancer Institute

    5/1/18 → 4/30/22

    Project: Research project

    • Research Output

    • 3498 Citations
    • 47 Article
    • 7 Review article
    • 1 Comment/debate
    • 1 Editorial

    Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy

    Basher, F., Dhar, P., Wang, X., Wainwright, D. A., Zhang, B., Sosman, J., Ji, Z. & Wu, J. D., Jun 9 2020, In : Journal of hematology & oncology. 13, 1, 1 p.

    Research output: Contribution to journal › Article

    Open Access

    • Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study

    Meyers, T. J., Weiner, A. B., Graff, R. E., Desai, A. S., Cooley, L. F., Catalona, W. J., Hanauer, S. B., Wu, J. D., Schaeffer, E. M., Abdulkadir, S. A., Kundu, S. D. & Witte, J. S., 2020, (Accepted/In press) In : International Journal of Cancer.

    Research output: Contribution to journal › Article

    • How else can we approach prostate cancer biomarker discovery?

    Drake, R. R., Angel, P. M., Wu, J., Pachynski, R. K. & Ippolito, J. E., Feb 1 2020, In : Expert Review of Molecular Diagnostics. 20, 2, p. 123-125 3 p.

    Research output: Contribution to journal › Editorial

    Open Access
    1 Scopus citations

    Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies

    Zhai, L., Bell, A., Ladomersky, E., Lauing, K. L., Bollu, L., Sosman, J. A., Zhang, B., Wu, J. D., Miller, S. D., Meeks, J. J., Lukas, R. V., Wyatt, E. J., Doglio, L., Schiltz, G. E., McCusker, R. H. & Wainwright, D. A., Jun 16 2020, In : Frontiers in immunology. 11, 1185.

    Research output: Contribution to journal › Review article

    Open Access

    • Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

    Zhang, J., Larrocha, P. S. L., Zhang, B., Wainwright, D., Dhar, P. & Wu, J. D., Aug 26 2019, In : Journal for immunotherapy of cancer. 7, 1, 223.

    Research output: Contribution to journal › Article

    Open Access
    • 3 Scopus citations